Avidity biosciences to participate in upcoming investor conferences

La jolla, calif., march 25, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called antibody oligonucleotide conjugates (aocs™), today announced that management will be participating in the following virtual investor conferences: guggenheim healthcare talks—genomic medicines and rare disease day conference thursday, april 1 st, 2021, 6:00 am pdt panel on duchenne muscular dystrophy (dmd) participants include: arthur levin, phd, chief scientific officer, avidity biosciences michael binks, md, vice president of clinical research, pfizer louise rodino-klapac, phd, chief scientific officer, sarepta therapeutics carl morris, phd, chief scientific officer, solid biosciences sam wadsworth, chief scientific officer, ultragenyx pharmaceutical 2021 virtual wells fargo biotech corporate access day tuesday, april 6 th, 2021 avidity management participation in investor 1x1 meetings 20th annual needham virtual healthcare conference monday, april 12 th, 2021, 12:45pm pdt webcast presentation live webcasts of the guggenheim panel and needham presentation will be available on the investors section of avidity's website and a replay of both events archived on the site.
RNA Ratings Summary
RNA Quant Ranking